Harmony Asset Management LLC acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,140 shares of the pharmaceutical company’s stock, valued at approximately $2,878,000. Vertex Pharmaceuticals comprises 1.2% of Harmony Asset Management LLC’s investment portfolio, making the stock its 23rd biggest holding.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Aveo Capital Partners LLC lifted its holdings in shares of Vertex Pharmaceuticals by 77.3% in the 4th quarter. Aveo Capital Partners LLC now owns 1,076 shares of the pharmaceutical company’s stock valued at $438,000 after buying an additional 469 shares during the period. Gryphon Financial Partners LLC lifted its holdings in Vertex Pharmaceuticals by 26.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,978 shares of the pharmaceutical company’s stock valued at $805,000 after acquiring an additional 414 shares during the period. Trexquant Investment LP boosted its position in Vertex Pharmaceuticals by 161.2% in the 4th quarter. Trexquant Investment LP now owns 3,968 shares of the pharmaceutical company’s stock worth $1,615,000 after purchasing an additional 2,449 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $33,000. Finally, US Bancorp DE grew its stake in shares of Vertex Pharmaceuticals by 46.3% during the 4th quarter. US Bancorp DE now owns 19,162 shares of the pharmaceutical company’s stock worth $7,797,000 after purchasing an additional 6,065 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.
Insider Transactions at Vertex Pharmaceuticals
In related news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at $20,320,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Bruce I. Sachs sold 5,295 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the sale, the director now directly owns 40,000 shares in the company, valued at approximately $20,320,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. The disclosure for this sale can be found here. Insiders sold 34,047 shares of company stock worth $16,843,806 in the last 90 days. Insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Stock Performance
NASDAQ VRTX opened at $464.92 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. The stock’s fifty day moving average is $482.66 and its two-hundred day moving average is $452.40. The firm has a market capitalization of $119.97 billion, a P/E ratio of 30.17 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $341.85 and a fifty-two week high of $510.64.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same period in the previous year, the firm posted $3.53 EPS. The company’s revenue was up 6.1% compared to the same quarter last year. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- What Are the FAANG Stocks and Are They Good Investments?
- Darden Restaurants Is on the Verge of a Significant Breakout
- How to Use the MarketBeat Excel Dividend Calculator
- Onsemi Could Be Set Up For a Solid Rebound: Here’s Why
- What is Put Option Volume?
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.